NICEVIVA
MONOGRAPH SPEC LATEST 2025

Thymus Extract

IMMUNE · Evidence Monograph

Thymus Extract is an evidence-graded immune monograph evaluated across 15 peer-reviewed PubMed studies (3 meta-analyses, 2 systematic reviews, and 2 randomized controlled trials, encompassing n = 492 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 15 Studies
Meta-Analyses · Reviews 3 Meta · 2 Systematic Reviews
Randomized Trials (RCT) 2 RCTs (2 Double-Blind)
Cumulative Participants n = 492
Reported Trial Dosages 700 mg · 1400 mg · 1.7 g
Trial Duration Range 12 weeks · 6 months · 3 months
Reading Time ~8 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support (supported by 15 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (700 mg · 1400 mg · 1.7 g) over a structured 12 weeks evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Clinically Standardized Formulation
Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.
Dose Adjustment Signal: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
With Breakfast or Lunch
Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary immune clinical efficacy (15 PubMed studies)
Quantitative biomarker & outcome analysis (7 studies with effect-size/sample data)
Randomized controlled trial verification (2 RCTs · 2 double-blind)
Systematic review & meta-analysis synthesis (3 meta-analyses · 2 reviews)
01

What Is Thymus Extract & Why Does Form Matter?

Thymus Extract is classified under IMMUNE and has been investigated across 15 peer-reviewed PubMed publications for its role in targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (700 mg, 1400 mg, 1.7 g).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Thymus Extract frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (2 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Thymus Extract acts on pathways governing targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Thymus Extract an overall evidence rating of GRADE High (4.0 / 4.0) based on 15 PubMed studies: 3 meta-analyses, 2 systematic reviews, and 2 randomized controlled trials (2 double-blind, n = 492 total participants).

Representative peer-reviewed findings include: • PMID:10554540 (1999) — "[Immunomodulating therapy of psoriasis vulgaris]." (The functional markers phagocytosis-associated chemiluminescence and nitroblue tetrazolium reduction were more enhanced (up to 4-fold with 1000 micrograms/ml Thymex-L) than morphology.) • PMID:7696339 (1995) — "The thymus extract Thymex-L potentiates the retinoic acid-induced differentiation of the human myeloid leukemia cell line HL-60." (Schulze-Forster K(1), Eckert K, Maurer HR.) • PMID:1227839 (1975) — "A thymic factor increasing the blood sugar level." (Both the thymectomy and the thymic factor increase the effect of alloxan and this sensitizing effect can be prevented by pretreatment with prednisolone.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Clinically Standardized Formulation. Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 700 mg · 1400 mg · 1.7 g · 8 mg over 12 weeks · 6 months · 3 months · 8 weeks. Optimal timing window: PM 12:30 · With Breakfast or Lunch (Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.

Adjustment & Discontinuation Signals: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Thymus Extract, but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (700 mg · 1400 mg · 1.7 g) and re-evaluate efficacy after 12 weeks.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (15 Studies) · 7 Quantitative Analyses

01
CLINICAL STUDY Medizinische Klinik (Munich, Germany (1999) PMID: 10554540 ↗
[Immunomodulating therapy of psoriasis vulgaris].
Clinical Trial Synthesis 1999 Clinical Study published in Medizinische Klinik (Munich, Germany. Key conclusion: The functional markers phagocytosis-associated chemiluminescence and nitroblue tetrazolium reduction were more enhanced (up to 4-fold with 1000 micrograms/ml Thymex-L) than morphology.
View Original PubMed Abstract ↓

BACKGROUND: Newest studies have shown that psoriasis is not primarily a skin disorder but an immunological disturbance under the skin. The skin manifestations are a result of overstimulation of superficial skin cells (Langerhans cells) due to increased production of interleukin 2, 6 and 8 as well as transforming growth-factor-alpha. Interleucin-10 production is diminished. In a recent study (11 German University Skin Clinics) fumaric acid was shown to improve the skin leasons in 80% of treated patients. OWN EXPERIENCES: Our own studies on 54 patients which where treated in addition with intravenous thymus extract (Thymoject) and selenium (Selenase) showed a faster healing rate with fumaric acid alone. From these results one can postulate that the above treatments (fumaric acid, thymus and selenium) have a synergystic effect. CONCLUSIONS: Internal immunmodulating treatments should therefore have preference over external symptomatic treatments like UV-light, ointments, salt water bath, etc. The thymus extract Thymex-L potentiates the retinoic acid-induced differentiation of the human myeloid leukemia cell line HL-60. Schulze-Forster K(1), Eckert K, Maurer HR. Author information: (1)Department of Pharmaceutical Biochemistry, Free University of Berlin, Germany. The human promyelocytic cell line HL-60 can be differentiated with retinoic acid (RA) along the granulocytic pathway. Numerous studies have identified many synergistic combinations of RA with cytostatics, cytokines and other inducers. A combination of RA with the crude thymus extract Thymex-L increased differentiation of HL-60 cells as confirmed by two functional assays and morphology, whereas the extract itself did not show any effect. The functional markers phagocytosis-associated chemiluminescence and nitroblue tetrazolium reduction were more enhanced (up to 4-fold with 1000 micrograms/ml Thymex-L) than morphology. The effect was found over a wide RA concentration range (10(-11) - 10(-6) M) and was dependent on extract concentration. The half-maximal induction of both functional markers was reached at 400 micrograms/ml. To achieve the same effect with the combination in comparison with RA alone, an RA

02
CLINICAL STUDY Biochimica et biophysica acta (1995) PMID: 7696339 ↗
The thymus extract Thymex-L potentiates the retinoic acid-induced differentiation of the human myeloid leukemia cell line HL-60.
Clinical Trial Synthesis 1995 Clinical Study published in Biochimica et biophysica acta. Key conclusion: Schulze-Forster K(1), Eckert K, Maurer HR.
View Original PubMed Abstract ↓

2. Biochim Biophys Acta. 1995 Mar 16;1265(2-3):110-6. doi: 10.1016/0167-4889(94)00212-w. The thymus extract Thymex-L potentiates the retinoic acid-induced differentiation of the human myeloid leukemia cell line HL-60. Schulze-Forster K(1), Eckert K, Maurer HR. Author information: (1)Department

03
CLINICAL STUDY Endokrinologie (1975) PMID: 1227839 ↗
A thymic factor increasing the blood sugar level.
Clinical Trial Synthesis 1975 Clinical Study published in Endokrinologie. Key conclusion: Both the thymectomy and the thymic factor increase the effect of alloxan and this sensitizing effect can be prevented by pretreatment with prednisolone.
View Original PubMed Abstract ↓

182. Endokrinologie. 1975 Jul;65(2):198-204. A thymic factor increasing the blood sugar level. Csaba G. The thymus extract prepared by using isotonic NaC1 solution causes hyperglycaemy and the thymectomy, too, produces the same effect. Consequently, the active substance of the thymus is produced elsewhere in the organism and being stored within the thymus, gets into the extract by homogenizing its cells. Both the thymectomy and the thymic factor increase the effect of alloxan and this sensitizing effect can be prevented by pretreatment with prednisolone.

04
SYSTEMATIC REVIEW The breast journal (2006) PMID: 17238981 ↗
Complementary/Alternative therapies for the treatment of breast cancer. A systematic review of randomized clinical trials and a critique of current terminology.
Clinical Trial Synthesis 2006 Systematic Review published in The breast journal. Key conclusion: Encouraging but not fully convincing results emerged for melatonin.
View Original PubMed Abstract ↓

The objectives of this study was to evaluate and critically analyze all randomized clinical trials (RCTs) of ''alternative cancer cures'' (ACCs) for breast cancer. The electronic databases Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Allied and Complementary Medicine, Scirus, BIOSIS, CancerLit and CINAHL and for ongoing trials the MetaRegister at http://www.controlled-trials.com/ and the National Research Register at http://www.update-software.com/national/ were searched from their inception. Bibliographies of located studies were scanned. Unpublished or ongoing trials were identified through correspondence with experts in the field. Our own files were hand searched for further RCTs. Review methods included a systematic review of RCTs involving breast cancer patients treated with ACCs, survival, parameters indicative of tumor burden, disease progression, cancer recurrence, and cancer cure. Results were tabulated and summarized. Thirteen RCTs met the inclusion criteria. In most cases their methodological quality is low, with only two RCTs scoring ''4'' and four RCTs scoring ''3'' out of 5 possible points for methodological quality. The treatments tested included various methods of psychosocial support such as group support therapy, cognitive behavioral therapy cognitive existential group therapy, a combination of muscle relaxation training and guided imagery, the Chinese herbal remedy Shi Quan Da Bu Tang, thymus extract, transfer factor, melatonin, and factor AF2. Encouraging but not fully convincing results emerged for melatonin.

05
RANDOMIZED TRIAL (RCT) Complementary therapies in medicine (2018) PMID: 30477827 ↗
The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: A randomized double-blind placebo-controlled clinical trial.
Clinical Trial Synthesis 2018 Randomized Controlled Trial (RCT) published in Complementary therapies in medicine involving n = 85 participants; statistical significance reported at p = 0.03. Key conclusion: CONCLUSION: ZM supplementation with daily dose of 1400 mg for 12 weeks improved insulin resistance in patients with NAFLD.
View Original PubMed Abstract ↓

OBJECTIVE: The aim of the study is to evaluate the effects of Zataria multiflora Boiss. (Shirazi thyme) (ZM) supplementation on nonalcoholic fatty liver disease (NAFLD) and related insulin resistance (IR). DESIGN: In this randomized double-blind placebo-controlled clinical trial, 85 patients with NAFLD were administered either 700 mg ZM powder or placebo twice daily for 12 weeks. All patients were advised to follow the recommendations for diet modification. RESULTS: ZM supplementation resulted in a significant reduction in serum insulin level (-2.72 ± 0.80 vs -0.67 ± 0.90, P=0.030), insulin resistance (-0.80 ± 0.22 vs 0.06 ± 0.22, P=0.023), systolic (-3.44 ± 1.05 vs 1.03 ± 0.98, P= 0.002) and diastolic (-2.33 ± 0.77 vs 0.26 ± 0.63, P= 0.009) blood pressure in patients with NAFLD in comparison with the placebo group. There was no significant difference between two groups regarding serum levels of alanine aminotransferase (ALT), high sensitive C-reactive protein (hs-CRP), Tumor necrosis factor-α (TNF-α), grade of fatty liver in ultrasonography, lipid profiles, and other outcomes. CONCLUSION: ZM supplementation with daily dose of 1400 mg for 12 weeks improved insulin resistance in patients with NAFLD. Further studies with longer duration and larger sample size are recommended.

06
CLINICAL STUDY Poultry science (2015) PMID: 26362978 ↗
Effect of plant extracts derived from thyme on male broiler performance.
Clinical Trial Synthesis 2015 Clinical Study published in Poultry science; statistical significance reported at p = 0.05. Key conclusion: These results suggest that dietary supplementation with TOE, especially at the level of 100 ppm, can improve immunological responses of broiler chicks.
View Original PubMed Abstract ↓

The effect of dietary thyme-oil extract (TOE) supplementation on immune functions of broilers were assessed by feeding graded levels (50, 100, 200, or 400 ppm) of TOE to male broiler chicks during a 42-d feeding trial compared with negative- or positive-control diets. Dietary control treatments included a negative-control diet with no feed-additive supplementation and 2 positive-control groups supplemented with either virginiamycin or zinc bacitracin. In total, 300 1-day-old Ross × Ross male broilers were randomly assigned to 6 dietary treatments that consisted of 5 replicates of 10 birds each. On d 21 and 42, 2 birds from each replicate were killed by cervical cutting to measure the relative weights of spleen and bursa of Fabricius. At 25 d of age, chicks were injected with 0.5 mL of 10% SRBC suspension. Broilers fed with 200 ppm of TOE had heavier weights of bursa of Fabricius than those fed other dietary treatments at d 42 of age. Furthermore, dietary inclusion of 100 ppm of TOE resulted in higher (P < 0.05) total immunoglobulin response in primary antibody titer against sheep erythrocytes compared with other dietary treatments. On the other hand, diet modifications had no significant effect on blood leukocyte subpopulations and heterophil-to-lymphocyte ratio. These results suggest that dietary supplementation with TOE, especially at the level of 100 ppm, can improve immunological responses of broiler chicks. © 2015 Poultry Science Association Inc.

07
CLINICAL STUDY Poultry science (2014) PMID: 24864291 ↗
Forsythia suspensa extract attenuates corticosterone-induced growth inhibition, oxidative injury, and immune depression in broilers.
Clinical Trial Synthesis 2014 Clinical Study published in Poultry science; statistical significance reported at p = 0.01. Key conclusion: In conclusion, dietary FSE supplementation enhanced nutrient digestibility and performance of broiler possibly by reducing oxidative stress and immune depression challenged by CS.
View Original PubMed Abstract ↓

Forsythia suspensa extract (FSE) has been demonstrated to attenuate physiological stress induced by high temperature or high stocking density. This experiment was conducted with 144 male Arbor Acre broilers (1-d-old, weighing 42.7 ± 1.7 g) to determine the effects of FSE on performance, nutrient digestibility, antioxidant activities, serum metabolites, and immune parameters for birds treated with corticosterone (CS). The birds were randomly allotted to 1 of 4 treatments in a 2 × 2 factorial arrangement that included FSE supplementation (0 or 100 mg/kg) and CS administration (0 or 20 mg/kg of diet for 7 consecutive days starting on d 14). The feeding program consisted of a starter diet from d 1 to 21 and a finisher diet from d 22 to 42. Corticosterone administration decreased (P < 0.01) ADG and impaired (P < 0.01) feed conversion ratio in both phases and overall, which were alleviated (P < 0.01) by dietary FSE supplementation in the finisher phase and overall. At d 21, CS administration caused decreases (P < 0.05) in the apparent digestibility of energy, relative weight of bursa and thymus, total antioxidant capacity, superoxide dismutase (SOD) activity, and antibody titers to Newcastle disease virus (NDV); however, serum malondialdehyde and uric acid were increased. All of these changes were attenuated (P < 0.05) by dietary FSE supplementation. At d 42, FSE supplementation improved (P < 0.05) the apparent digestibility of DM and CP, relative weights of bursa, SOD activity, and antibody titers to NDV, which were impaired by CS administration. Interactions (P < 0.05) were noted between CS and FSE for ADG and feed conversion ratio in the finisher phase and overall, as well as total antioxidant capacity, SOD activity, uric acid, and antibody titers to NDV at d 21, as well as relative weights of thymus at d 42. In conclusion, dietary FSE supplementation enhanced nutrient digestibility and performance of broiler possibly by reducing oxidative stress and immune depression challenged by CS. © 2014 Poultry Science Association Inc.

08
CLINICAL STUDY Journal of environmental biology (2011) PMID: 22319873 ↗
Effects of pitamin on growth performance, carcass characteristics and cecal microflora of broiler chicken.
Clinical Trial Synthesis 2011 Clinical Study published in Journal of environmental biology; statistical significance reported at p = 0.05. Key conclusion: In conclusion, when Korean red pine bark extract, pitamin, was added to the broiler diets at a concentration of 70 mg of pitamin kg(-1) of diet, it resulted in better growth performance as compared to the antibiotics by improving immunity and the cecal beneficial microfloral popu
View Original PubMed Abstract ↓

The aim of this study is to determine the effect of dietary pitamin as an antibiotic replacement in broiler chicken. The treated groups were as follows: 1) the control, 2) the antibiotics (8 mg of avilamycin kg(-1) of diet) and 3) the pitamin (70 mg of pitamin kg(-1) of diet) groups. Body weight gain, feed intake, and feed efficiency were significantly higher in the pitamin group than in the antibiotics and control groups (p<0.05). Carcass weight, dressing percentage, and the weight of breast and thigh muscle recorded significantly higher levels in the pitamin group as compared to the other groups (p<0.05). The addition of pitamin to the diets for broilers reduced abdominal fat by 23.35% and stimulated the growth of the thymus, the spleen, and the bursa of Fabricius. TAG levels of the pitamin group declined by 12.03 and 10.45% as compared to the control and antibiotics groups, and their TC levels were reduced by 15.17 and 14.39%, and LDL. C levels were reduced by 10.56 and 11.24%, respectively. Serum IgG was increased significantly by 137.43 and 36.80% in the pitamin group as compared to the control and antibiotics groups, respectively (p<0.05). The numbers of Bifidobacterium and Lactobacillus on the cecum digesta were significantly higher in the pitamin group than in the antibiotics and control groups and the numbers of Escherichia coli and Salmonella tended to be reduced (p<0.05). In conclusion, when Korean red pine bark extract, pitamin, was added to the broiler diets at a concentration of 70 mg of pitamin kg(-1) of diet, it resulted in better growth performance as compared to the antibiotics by improving immunity and the cecal beneficial microfloral population.

09
CLINICAL STUDY The British journal of nutrition (2012) PMID: 21787453 ↗
Effects of yeast cell walls on performance and immune responses of cyclosporine A-treated, immunosuppressed broiler chickens.
Clinical Trial Synthesis 2012 Clinical Study published in The British journal of nutrition. Key conclusion: These results indicate that YCW supplementation has beneficial effects in attenuating the immunosuppressive effects of CSA challenge, therefore improving growth performance of broiler chickens.
View Original PubMed Abstract ↓

The present study was conducted to investigate the effects of dietary yeast (Saccharomyces cerevisiae) cell walls (YCW) from the yeast extract industry on performance and immune function of cyclosporine A (CSA)-treated, immunosuppressed broiler chickens. A total of 240 day-old male broilers were allocated randomly into four treatments: (1) non-challenged control; (2) non-challenged control+0·3 % YCW; (3) CSA-challenged group; (4) CSA-challenged+0·3 % YCW. On days 1-4 and 22-25 of age, broilers were subcutaneously injected with CSA or sterile saline. The results showed that supplementation of YCW significantly improved daily weight gain (DWG) during the starter (days 1-21, P < 0·01), finisher (days 22-42, P < 0·01) and overall (days 1-42, P < 0·05) periods compared with the control birds, but had no effect on feed conversion ratio (FCR, P>0·05). Compared with the CSA-treated birds, YCW alleviated the decrease of DWG (P < 0·01) and increase of FCR (P < 0·05) caused by CSA challenge at different periods and cumulatively. On days 21 and 42, YCW mitigated the CSA-induced decrease of peripheral blood lymphocyte blastogenic response (P < 0·01). In addition, YCW improved the relative weights of the bursa of Fabricius (P < 0·01) and thymus (P < 0·01) and up-regulated the splenic expression of pro-inflammatory cytokines IL-1β (P < 0·01) and IL-6 (P < 0·01) on day 42 compared with the CSA-treated birds. These results indicate that YCW supplementation has beneficial effects in attenuating the immunosuppressive effects of CSA challenge, therefore improving growth performance of broiler chickens.

10
CLINICAL STUDY FEMS immunology and medical microbiology (2006) PMID: 16553814 ↗
A new synbiotic, Lactobacillus casei subsp. casei together with dextran, reduces murine and human allergic reaction.
Clinical Trial Synthesis 2006 Clinical Study published in FEMS immunology and medical microbiology. Key conclusion: casei and dextran in humans led to no significant changes in total nasal and ocular symptom scores, in the levels of cedar pollen-specific immunoglobulin E, interferon-gamma and thymus and activation regulated chemokine or in the number of eosinophils in sera, whereas the placebo
View Original PubMed Abstract ↓

We studied the development of atopic dermatitis-like skin lesions in NC/Nga mice and the allergic symptoms and blood patterns of healthy volunteers during the cedar (Cryptomeria japonica) pollen season in Japan following oral administration of a new synbiotic, Lactobacillus casei subsp. casei together with dextran. The combination of L. casei subsp. casei and dextran significantly decreased clinical skin severity scores and total immunoglobulin E levels in sera of NC/Nga mice that had developed picryl chloride-induced and Dermatophagoides pteronyssinus crude extract-swabbed atopic dermatitis-like skin lesions. During the most common Japanese cedar pollen season, synbiotic L. casei subsp. casei and dextran in humans led to no significant changes in total nasal and ocular symptom scores, in the levels of cedar pollen-specific immunoglobulin E, interferon-gamma and thymus and activation regulated chemokine or in the number of eosinophils in sera, whereas the placebo group showed a tendency for increased levels of cedar pollen-specific immunoglobulin E, thymus and activation regulated chemokine and number of eosinophils, and a decrease in interferon-gamma levels. Thus, the oral administration of synbiotic L. casei subsp. casei together with dextran appears to be an effective supplement for the prevention and treatment of allergic reactions.

RELATED MONOGRAPHS

Related Monographs in This Category